

Anti-epileptic drugs inhibit viability of synoviocytes *in vitro*

Jolanta Parada-Turska¹, Patrycja Nowicka-Stążka², Maria Majdan¹, Mirosław Jabłoński³, Waldemar A. Turski^{2,4}, Wojciech Rzeski^{5,6}

¹ Department of Rheumatology and Connective Tissue Diseases, Medical University, Lublin, Poland

² Department of Experimental and Clinical Pharmacology, Medical University, Lublin, Poland

³ Department of Orthopedics and Rehabilitation, Medical University, Lublin, Poland

⁴ Department of Toxicology, Institute of Rural Health, Lublin, Poland

⁵ Department of Medical Biology, Institute of Rural Health, Lublin, Poland

⁶ Department of Virology and Immunology, Institute of Microbiology and Biotechnology, Maria Curie-Skłodowska University, Lublin, Poland

Parada-Turska J, Nowicka-Stążka P, Majdan M, Jabłoński M, Turski WA, Rzeski W. Anti-epileptic drugs inhibit viability of synoviocytes *in vitro*. Ann Agric Environ Med. 2013; 20(3): 571–574.

Abstract

Introduction and objective: The hyperplasia of synovial fibroblasts is considered to be essential for the evolution of joint destruction in rheumatoid arthritis (RA). Previously, we reported that anti-rheumatic drugs, both COX inhibitors and disease-modifying anti-rheumatic drugs inhibit proliferation of synoviocytes *in vitro*. The presented study investigates the effect of anti-epileptic drugs on the viability and proliferation of synovial fibroblasts *in vitro*.

Methods: Experiments were conducted on human synoviocytes derived from an RA patient and rabbit synoviocytes cell line HIG-82. Cell proliferation and viability were assessed by means of BrdU assay and MTT assay, respectively. The IC₅₀ value (the concentration of drug necessary to induce 50% inhibition) together with confidence limits was calculated.

Results: Carbamazepine inhibited proliferation of human fibroblasts and viability of HIG-82 with IC₅₀ values of 86 μM and 82 μM, respectively. Diphenylhydantoin, valproate and phenobarbital inhibited viability of HIG-82 cells with the IC₅₀ values of 110, 500 and 1031 μM, respectively.

Conclusion: Based on these findings, it can be suggested that anti-epileptic drugs may have a disease-modifying effect on rheumatoid synovial proliferation.

Key words

anti-epileptic drugs, synoviocytes, proliferation, *in vitro*

INTRODUCTION

Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease affecting approximately 1% of the population. Recently, it was indicated that urbanization is associated with an increased prevalence of RA [1]. This finding suggests that environmental factors may affect RA development. The pathogenesis of RA is still not well understood. However, it is widely accepted that the inflammatory process in the synovial tissue is dominated by proliferation of activated synovial fibroblasts. They are considered to play an important role in both the initiation and progression of joint destruction in RA [2, 3, 4]. The hyperplasia of synovial fibroblasts is one of the most striking features of RA and is considered to be essential for the evolution of joint destruction in RA. Thus, it seems that control of synovial hyperplasia represents a target for novel therapeutic approaches for the inhibition of joint destruction.

Previously, we found that glutamate antagonists inhibit proliferation of HIG-82 synovial fibroblast *in vitro* with potency comparable to anti-rheumatic drugs, COX inhibitors: celecoxib, diclofenac, nimesulide, naproxen and disease-modifying anti-rheumatic drugs, methotrexate

and sulfasalazine, and suggested that glutamate receptor antagonists may have a disease modifying effect on rheumatoid synovial proliferation [5].

Recently, anti-epileptic drugs, valproic acid and carbamazepine were found to inhibit histone deacetylases [6] which regulate expression of tumour suppressor genes and activities of transcriptional factors involved in cancer cells proliferation. The therapeutic anti-cancer potential of valproic acid in monotherapy or combined with other anti-tumour drugs is currently being tested in several clinical trials (see for review: [7]).

Therefore, the aim of the presented study was to investigate the effects of anti-convulsant drugs commonly used in the treatment of epilepsy on the proliferation of synovial fibroblasts *in vitro*. Diphenylhydantoin, phenobarbital, and two histone deacetylase inhibitors: valproate and carbamazepine were chosen.

MATERIALS AND METHODS

Drugs

Carbamazepine, diphenylhydantoin, valproate were purchased from Sigma-Aldrich (St. Louis, USA). Phenobarbital was obtained from Polfa (Cracow, Poland). All other chemicals were purchased from commercial suppliers and were of the highest available purity.

Address for correspondence: Jolanta Parada-Turska, Department of Rheumatology and Connective Tissue Diseases, Medical University, Jaczewskiego 8, 20-950 Lublin, Poland.

e-mail: jolanta.turska@am.lublin.pl

Received: 10 October 2012; accepted: 05 February 2013

Human synoviocytes

Synovial tissue was obtained from the knee of a patient who fulfilled the American College of Rheumatology 1987 criteria for diagnosis of RA [8] at the time of synovectomy during total joint replacement as a standard clinical procedure. Primary synoviocyte cell culture was prepared as previously described [8]. Briefly, synovial tissue was processed within 2 h after harvesting from the patient. After discarding fat and fibrous tissue, the synovium was mechanically dispersed, cut into small pieces, and plated on 75 cm² plastic culture flasks (Nunc) in a culture medium consisting of Ham F-12 (Sigma), supplemented with 10% of FBS, 100 U/ml penicillin, 100 µg/ml streptomycin and 1% of antibiotic-antimycotic solution (Life Technologies). Cultures were kept at 37°C in a humidified atmosphere of 95% air and 5% CO₂. Culture medium was changed every 3 days. After reaching confluency, cells were subcultured by means of 0.25% Trypsin-ethylene diamine tetraacetic acid solution and subjected to experiments.

HIG-82 cell culture

In vitro experiments were conducted on rabbit synoviocytes cell line HIG-82 obtained from ATCC (American Type Culture Collection, Menassas, VA, USA). Culture medium consisted of Nutrient Mixture F-12 Ham (Sigma Chemicals, St. Louis, MO, USA) supplemented with 10% of FBS (Life Technologies, Karlsruhe, Germany), 100 U/ml penicillin (Sigma) and 100 µg/ml streptomycin (Sigma). Cultures were kept at 37°C in a humidified atmosphere of 95% air and 5% CO₂.

Cell proliferation assessment

5-bromo-2'-deoxy-uridine (BrdU) assay is an immunoassay for the quantification of BrdU incorporation into newly synthesized DNA of actively proliferating cells. Human rheumatoid arthritis fibroblasts-like synoviocytes were plated on 96-well microplates (Nunc, Roskilde, Denmark) at a density of 2×10^4 cells/ml. Next day, the culture medium was removed and the cells exposed to fresh medium (control) or serial dilutions carbamazepine (10–500 µM) in fresh medium. Cell proliferation was quantified after 48 h by measurement of BrdU incorporation during DNA synthesis, according to the manufacturer's procedure (Cell Proliferation ELISA BrdU, Roche Diagnostics GmbH, Penzberg, Germany).

Cell viability assessment

HIG-82 cells were plated on 96 well microplates (NUNC, Roskilde, Denmark) at a density of 1×10^4 cells/ml. Next day, the culture medium was changed and cells exposed to serial dilutions of tested compounds. Cell viability was assessed after 96 h by means of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (Cell proliferation kit I, Roche Diagnostics GmbH, Penzberg, Germany). HIG-82 cells were incubated for 3 h with MTT solution (5 mg/ml). Formazan crystals were solubilized overnight in SDS buffer, and the product quantified spectrophotometrically by measuring absorbance at 570 nm wavelength using E-max Microplate Reader (Molecular Devices Corporation, Menlo Park, CA, USA).

Data analysis

Results are expressed as a percentage of the control. The mean value and standard deviation of (SD) was calculated from 6–7 independent experiments.

The IC₅₀ value (the concentration of drug necessary to induce 50% inhibition), together with confidence limits, was calculated using computerised linear regression analysis of quantal log dose-probit functions, according to the method of Litchfield and Wilcoxon [9].

RESULTS

The proliferation of human synovial fibroblasts determined by means of the quantification of BrdU incorporation into newly synthesized DNA of proliferating cells was inhibited by carbamazepine in a dose-dependent fashion (Fig. 1) with IC₅₀ values of 86 (65–115) µM.




Figure 1. Effect of carbamazepine on the proliferation and viability of human rheumatoid arthritis fibroblasts-like synoviocytes *in vitro* (BrdU assay) and rabbit synoviocytes cell line HIG-82 *in vitro* (MTT assay). Results are expressed as percentage of control; mean \pm SD; n = at least 7 independent experiments. Circles and continuous line represent human rheumatoid arthritis fibroblasts-like synoviocytes; squares and dashed line represent rabbit synoviocytes cell line HIG-82. Regression curves were calculated using GraphPAD software. Human rheumatoid arthritis fibroblasts-like synoviocytes (solid line): $y = -0.1402x + 75.237$, $r = -0.87$; rabbit synoviocytes cell line HIG-82 (dashed line): $y = -0.1353x + 74.408$, $r = -0.96$.

The viability of rabbit synovial fibroblasts HIG-82 determined by means of tetrazolium salt reduction in living cells was inhibited by antiepileptic drugs, carbamazepine (Fig. 1), diphenylhydantoin, valproate and phenobarbital dose-dependently with the IC₅₀ values of 82, 110, 500 and 1031 µM, respectively (Tab. 1).

Table 1. Effect of anti-epileptic drugs on the viability of rabbit synoviocytes cell line HIG-82 *in vitro*

Drug	IC ₅₀ [µM]	95% confidence limits
Carbamazepine	82	47–142
Diphenylhydantoin	110	64–189
Valproate	500	435–576
Phenobarbital	1031	815–1303

IC₅₀ – the concentration of drug necessary to induce 50% inhibition

DISCUSSION

It was found that carbamazepine in micromolar concentrations inhibited proliferation of human rheumatoid arthritis fibroblasts-like synoviocytes *in vitro*. It decreased viability of rabbit synovial fibroblast HIG-82 which shares

many of the characteristics of activated human rheumatoid synovium [10] in similar concentrations. Diphenylhydantoin, valproate and phenobarbital affected the viability of HIG-82 less effectively. It should be emphasised that the viability of these cells was decreased also by anti-rheumatic drugs, COX inhibitors: celecoxib, diclofenac, nimesulide, naproxen and disease-modifying anti-rheumatic drugs, methotrexate and sulfasalazine. Interestingly, the antiproliferative potential of antiepileptic drugs is comparable to that of anti-rheumatic drugs [5].

Publications dealing with the effect of carbamazepine on cell proliferation are sparse. It has been reported that carbamazepine induced mitotic arrest and inhibited proliferation in mammalian Vero cells (with IC_{50} value of 406 μ M) [11], human choriocarcinoma cell line (BeWo) [12] and inhibited the proliferation of breast cancer cell lines MCF-7 and T47D stimulated by estradiol (in concentration 10–1000 μ M) [13]. On the other hand, no effect of carbamazepine on the proliferation of human malignant glioma cells [14], human neuroblastoma cells SH-SY5Y [15] and mouse splenocytes [16] was found. The effect of valproate on fibroblast proliferation has never been reported before. However, its anti-proliferative properties were found in numerous cell lines, e.g. rat glomerular mesangial cells [17], human hepatoblastoma cells HepG2 [18], human hepatocellular cancer cells HuH7 [19], human gastric carcinoma cells BGC-823 [20] and human coronary vascular cells [21].

On the contrary, diphenylhydantoin is known to stimulate proliferation of gingival fibroblast [22, 23] and skin fibroblasts [24, 25]. This effect is attributed to low nanomolar concentrations [22, 23, 25]. At higher concentrations it was reported to inhibit proliferation of human skin fibroblasts [25], mouse muscle cells [26] and mouse embryonic palatal mesenchymal cells [27]. These results point to the biphasic, dose- and time-dependent effect of diphenylhydantoin on cell proliferation *in vitro*. No report on the effect of phenobarbital on cell proliferation has been found. The molecular mechanism of anti-proliferative action of anti-epileptic drugs has to be elucidated. It seems that it is not directly linked to histone deacetylase inhibition.

The comparison of anti-proliferative activity of anti-epileptic drugs expressed as IC_{50} with their plasma concentrations recommended in the treatment of epilepsy suggests their potential clinical application in RA prevention. The plasma concentration of valproate is 300–600 μ M [28] or 347–833 μ M [29] and its anti-proliferative IC_{50} value was 500 μ M. Similarly, the anti-proliferative concentrations of carbamazepine (82 μ M) and diphenylhydantoin (110 μ M) are close to their anti-epileptic plasma concentrations 16–48 μ M [28] or 17–51 μ M [29] and 40–80 μ M [28, 29], respectively. On the contrary, anti-proliferative concentration of phenobarbital *in vitro* (1031 μ M) is distinctly higher than its anti-epileptic range *in vivo* (15–40 μ M or 64–172 μ M) [28, 29]. Thus, considering the therapeutic concentrations of anti-epileptic drugs recommended for the treatment of epilepsy the most effective and promising one among the studied drugs is valproate. Both, carbamazepine and phenytoin exerted inhibitory action at concentrations nominally higher than their respective therapeutic ranges against epilepsy. However, the low cost of drugs and acceptable toxicity of these drugs do not rule out their use as disease-modifying anti-rheumatic drugs. In this context, phenobarbital can be

excluded. Unexpectedly, to the best of our knowledge, there is no analysis in the literature of the efficacy of anti-epileptics in RA patients.

Summing up, the presented study reports for the first time that anti-epileptic drugs inhibit the viability and proliferation of synovial fibroblasts *in vitro*. Based on these findings, it can be suggested that anti-epileptic drugs may have a disease-modifying effect on rheumatoid synovial proliferation. Since the most effective drugs in the presented study were an experimental paradigm, whereas carbamazepine, diphenylhydantoin and valproate, are widely used in clinical practice and it should be possible to establish a meta-analysis or clinical proof of the concept.

Acknowledgements

This study was supported in part by the State Committee for Scientific Research (Poland), Grant No. 2P05A03827.

REFERENCES

- Tobon GJ, Youinou P, Saraux A. The environment, geo-epidemiology, and autoimmune disease: Rheumatoid arthritis. *J Autoimmun.* 2010; 35: 10–14.
- Mor A, Abramson SB, Pillinger MH. The fibroblast-like synovial cell in rheumatoid arthritis: a key player in inflammation and joint destruction. *Clin Immunol.* 2005; 115: 118–128.
- Huber LC, Distler O, Turner I, Gay RE, Gay S, Pap T. Synovial fibroblasts: key players in rheumatoid arthritis. *Rheumatology (Oxford).* 2006; 45: 669–675.
- Bartok B, Firestein GS. Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. *Immunol Rev.* 2010; 233: 233–255.
- Parada-Turska J, Rzeski W, Majdan M, Kandefer-Szerszen M, Turski WA. Effect of glutamate receptor antagonists and antirheumatic drugs on proliferation of synoviocytes *in vitro*. *Eur J Pharmacol.* 2006; 535: 95–97.
- Beutler AS, Li S, Nicol R, Walsh MJ. Carbamazepine is an inhibitor of histone deacetylases. *Life Sci.* 2005; 76: 3107–3115.
- Tan J, Cang S, Ma Y, Petrillo RL, Liu D. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. *J Hematol Oncol.* 2010; 3: 5.
- Parada-Turska J, Mitura A, Brzana W, Jablonski M, Majdan M, Rzeski W. Parthenolide inhibits proliferation of fibroblast-like synoviocytes *in vitro*. *Inflammation.* 2008; 31: 281–285.
- Litchfield JT, Wilcoxon F. A simplified method of evaluating dose-effect experiments. *J Pharmacol Exp Ther.* 1949; 96: 99–113.
- Georgescu HI, Mendelow D, Evans CH. HIG-82: an established cell line from rabbit periarticular soft tissue, which retains the “activatable” phenotype. *In Vitro Cell Dev Biol.* 1988; 24: 1015–1022.
- Perez Martin JM, Fernandez FP, Labrador V, Hazen MJ. Carbamazepine induces mitotic arrest in mammalian Vero cells. *Mutat Res.* 2008; 637: 124–133.
- Kwiecinska P, Wisniewska J, Gregoraszczyk EL. Effects of valproic acid (VPA) and levetiracetam (LEV) on proliferation, apoptosis and hormone secretion of the human choriocarcinoma BeWo cell line. *Pharmacol Rep.* 2011; 63: 1195–1202.
- Meng QW, Zhao CH, Xi YH, Cai L, Sun LC, Sui GJ. [Enhancement of HER-2 degradation by carbamazepine in breast cancer SKBR-3 cell line]. *Zhonghua Zhong Liu Za Zhi.* 2006; 28: 503–506.
- Stander M, Dichgans J, Weller M. Anticonvulsant drugs fail to modulate chemotherapy-induced cytotoxicity and growth inhibition of human malignant glioma cells. *J Neurooncol.* 1998; 37: 191–198.
- Di DE, Mudge AW, Maycox PR. Comparative analysis of the effects of four mood stabilizers in SH-SY5Y cells and in primary neurons. *Bipolar Disord.* 2005; 7: 33–41.
- Basta-Kaim A, Budziszewska B, Leskiewicz M, Kubera M, Jagla G, Nowak W, et al. Effects of new antiepileptic drugs and progabide on the mitogen-induced proliferative activity of mouse splenocytes. *Pharmacol Rep.* 2008; 60: 925–932.
- Freidkin I, Herman M, Tobar A, Chagnac A, Ori Y, Korzets A, et al. Effects of histone deacetylase inhibitors on rat mesangial cells. *Am J Physiol Renal Physiol.* 2010; 298: F426–F434.

18. Wang W, Liao XL, Chen JH, Li DD, Lin CL, Yan YX, et al. Sodium valproate induces mitochondria-dependent apoptosis in human hepatoblastoma cells. *Chin Med J (Engl)*. 2011; 124: 2167–2172.
19. Machado MC, Bellodi-Privato M, Kubrusly MS, Molan NA, Tharcisio T, Jr., de Oliveira ER, et al. Valproic acid inhibits human hepatocellular cancer cells growth in vitro and in vivo. *J Exp Ther Oncol*. 2011; 9: 85–92.
20. Zhao X, Yang W, Shi C, Ma W, Liu J, Wang Y, et al. The G1 phase arrest and apoptosis by intrinsic pathway induced by valproic acid inhibit proliferation of BGC-823 gastric carcinoma cells. *Tumour Biol*. 2011; 32: 335–346.
21. Voisard R, Krebs R, Baur R, Hombach V. Valproic acid inhibits proliferation of human coronary vascular cells (SI/MPL-ratio: 0.5): a novel candidate for systemic and local therapy of postinterventional restenosis. *Coron Artery Dis*. 2010; 21: 286–291.
22. Sano M, Ohuchi N, Inoue T, Tono K, Tachikawa T, Kizawa Y, et al. Proliferative response to phenytoin and nifedipine in gingival fibroblasts cultured from humans with gingival fibromatosis. *Fundam Clin Pharmacol*. 2004; 18: 465–470.
23. Ohuchi N, Koike K, Sano M, Kusama T, Kizawa Y, Hayashi K, et al. Proliferative effects of angiotensin II and endothelin-1 on guinea pig gingival fibroblast cells in culture. *Comp Biochem Physiol C Toxicol Pharmacol*. 2002; 132: 451–460.
24. Genever PG, Cunliffe WJ, Wood EJ. Influence of the extracellular matrix on fibroblast responsiveness to phenytoin using in vitro wound healing models. *Br J Dermatol*. 1995; 133: 231–235.
25. Moy LS, Tan EM, Holness R, Uitto J. Phenytoin modulates connective tissue metabolism and cell proliferation in human skin fibroblast cultures. *Arch Dermatol*. 1985; 121: 79–83.
26. Goyle S. Effect of phenytoin on proliferation and differentiation of mouse muscle cells in vitro. *Methods Find Exp Clin Pharmacol*. 1983; 5: 143–148.
27. Hu X, Chen Z, Mao X, Tang S. Effects of phenytoin and Echinacea purpurea extract on proliferation and apoptosis of mouse embryonic palatal mesenchymal cells. *J Cell Biochem*. 2011; 112: 1311–1317.
28. Eadie MJ. Therapeutic drug monitoring—antiepileptic drugs. *Br J Clin Pharmacol*. 1998; 46: 185–193.
29. Warner A, Privitera M, Bates D. Standards of laboratory practice: antiepileptic drug monitoring. *National Academy of Clinical Biochemistry. Clin Chem*. 1998; 44: 1085–1095.